Detail publikace

Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis

STRMISKA, V. MICHÁLEK, P. LACKOVÁ, Z. GURÁŇ, R. KŘÍŽKOVÁ, S. POMPEIANO VANÍČKOVÁ, L. ZÍTKA, O. STIBOROVÁ, M. ECKSCHLAGER, T. KLEJDUS, B. PACÍK, D. TVRDÍKOVÁ, E. KEIL, C. HAASE, H. ADAM, V. HEGER, Z.

Originální název

Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis

Typ

článek v časopise ve Web of Science, Jimp

Jazyk

angličtina

Originální abstrakt

DNA hypermethylation is one of the most common epigenetic modifications in prostate cancer (PCa). Several studies have delineated sarcosine as a PCa oncometabolite that increases the migration of malignant prostate cells while decreasing their doubling time. Here, we show that incubation of prostate cells with sarcosine elicited the upregulation of sarcosine N-demethylation enzymes, sarcosine dehydrogenase and pipecolic acid oxidase. This process was accompanied by a considerable increase in the production of the major methyl-donor S-adenosylmethionine (SAMe), together with an elevation of cellular methylation potential. Global DNA methylation analyses revealed increases in methylated CpG islands in distinct prostate cell lines incubated with sarcosine, but not in cells of nonprostate origin. This phenomenon was further associated with marked upregulation of DNA methyltransferases (Dnmts). Epigenetic changes were recapitulated through blunting of Dnmts using the hypomethylating agent 5-azacytidine, which was able to inhibit sarcosine- induced migration of prostate cells. Moreover, spatial mapping revealed concomitant increases in sarcosine, SAMe and Dnmt1 in histologically confirmed malignant prostate tissue, but not in adjacent or nonmalignant tissue, which is in line with the obtained in vitro data. In summary, we show here for the first time that sarcosine acts as an epigenetic modifier of prostate cells and that this may contribute to its oncometabolic role.

Klíčová slova

DNA methylation; Dnmts; epigenetics; prostate cancer; SAMe; sarcosine

Autoři

STRMISKA, V.; MICHÁLEK, P.; LACKOVÁ, Z.; GURÁŇ, R.; KŘÍŽKOVÁ, S.; POMPEIANO VANÍČKOVÁ, L.; ZÍTKA, O.; STIBOROVÁ, M.; ECKSCHLAGER, T.; KLEJDUS, B.; PACÍK, D.; TVRDÍKOVÁ, E.; KEIL, C.; HAASE, H.; ADAM, V.; HEGER, Z.

Vydáno

31. 5. 2019

Nakladatel

FEBS Press

ISSN

1574-7891

Periodikum

MOL ONCOL

Ročník

13

Číslo

5

Stát

Spojené království Velké Británie a Severního Irska

Strany od

1002

Strany do

1017

Strany počet

16

URL

https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12439

Plný text v Digitální knihovně

http://hdl.handle.net/11012/180683

BibTex

@article{BUT155498,
  author="Vladislav {Strmiska} and Petr {Michálek} and Zuzana {Lacková} and Roman {Guráň} and Soňa {Křížková} and Lucie {Pompeiano Vaníčková} and Ondřej {Zítka} and Marie {Stiborová} and Tomáš {Eckschlager} and Bořivoj {Klejdus} and Dalibor {Pacík} and Eliška {Tvrdíková} and Claudia {Keil} and Hajo {Haase} and Vojtěch {Adam} and Zbyněk {Heger}",
  title="Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis",
  journal="MOL ONCOL",
  year="2019",
  volume="13",
  number="5",
  pages="1002--1017",
  doi="10.1002/1878-0261.12439",
  issn="1574-7891",
  url="https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12439"
}